SCHEMBL341092

SCHEMBL341092

COc1ccc(OC)c(C(=O)Nc2ccc(N3CCCC3)cc2C(C)=O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.57
MEN1 O00255 3/20 0.57
RXFP1 Q9HBX9 1/20 0.55
MAPT P10636 5/20 0.52
RAB9A P51151 4/20 0.52
NPC1 O15118 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
AHR P35869 1/20 0.52
GFER P55789 1/20 0.52
F10 P00742 8/20 0.51
LMNA P02545 2/20 0.49
POLB P06746 1/20 0.49
TP53 P04637 1/20 0.49
ALDH1A1 P00352 2/20 0.49
USP2 O75604 1/20 0.49
NR4A1 P22736 1/20 0.49
MCL1 Q07820 1/20 0.49
KEAP1 Q14145 1/20 0.48
NFE2L2 Q16236 1/20 0.48
QSOX1 O00391 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL340278 0.91 MEN1 (0.58) KMT2AMEN1MAPTF10POLB
SCHEMBL340111 0.87 RXFP1 (0.72) KMT2AMEN1RXFP1MAPTRAB9A
SCHEMBL340622 0.85 MAPT (0.68) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL339940 0.82 RXFP1 (0.62) KMT2AMEN1RXFP1MAPTRAB9A
SCHEMBL339593 0.77 BRPF1 (0.60) KMT2AMEN1RXFP1MAPTRAB9A
SCHEMBL341059 0.76 MEN1 (0.61) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL4465486 0.74 TP53 (0.72) KMT2AMEN1MAPTSMN1; SMN2LMNA
SCHEMBL339293 0.74 LRRK2 (0.63) KMT2AMEN1RXFP1MAPTRAB9A
SCHEMBL341381 0.73 MAPT (0.63) KMT2AMEN1MAPTRAB9ANPC1
SCHEMBL340604 0.73 RAB9A (0.56) KMT2AMEN1RXFP1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3112348-A1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES Tairx, Inc. (TW) 2017-01-04 EP disclosed
EP-2593435-B1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES TAIRX INC (TW) 2016-09-07 EP disclosed
US-8524740-B2 Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives TAIRX, INC. (TW) 2013-09-03 US disclosed
US-20120015908-A1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES Efficient Pharma Management Corporate (TW) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015908-A1 SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES SLC22A8, ABCC8, CYP2C8 KMT2A 2015/4885MEN1 2493/4885RXFP1 3003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.